Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That reminds me of a joke.
Two neutrinos walk through a bar.
Five decades ago, you were trying to convince your neighbors down the street that their lemonade stand would fail, whilst covertly investing in two other stands in the same ten block radius.
I’m starting to get cantankerous, maybe Merck should get swooped again…..a little voice inside my head gets louder. 🥸
Disagree. I think a good pharma, let’s say Amgen, Gilead or Regeneron knows the value, but doesn’t want it F___ up by certain someones, then they pay a lot early to take on the challenge and potential, rather than buy a cake left out in the rain too long. I’m getting old too, and I’ve seen companies flounder for years after approval due to resources, sharks (hedge funds/pharma/dirty media). They’re licking their chops. NWBO needs to trust some company.
NWBO has been crafty, politically patient and adept, but everyone bows to Father Time. I still think it should function as a wholly owned subsidiary, but Jeez, not going it alone much longer.
Nice process is “in progress.” The stakeholders have been notified. Reimbursement the old fashioned way for something like this will take over three months, particularly with automation factored in, which means interim funding from the MHRA needs to be considered. Companies don’t get standard NICE reimbursement decisions before approval nor shortly thereafter.
One starts in the UK when one is building a new industry starting with compassionate manufacturing, expanding to manual commercial demand in an appropriately sized market then moving to global automated closed system manufacturing.
They already announced they plan to file nearly duplicate MAAs in additional markets.
Exwannabe stated:
Exwannabe said:
Good effort, but Julia Childs must be turning over on her strawberry cloud.
It’s a stretch to call approval the end of a trial.
You said:
Toucan has nine lives.
That song is messed up.
1. It doesn’t take a long time to bake a cake.
2. How the hell could he not know who put the cake out in the rain.
3. And why’d his recipe disappear forever? Did he bake it with the cake, because the cake in the rain didn’t cause a recipe to disappear now did it?
The Prometheus timeline has been discussed previously. I think what Hoffman is skimping on is:
1. August 9, 2023 actually was discussing the second quarter which ended June 30, 2023.
2. The likelihood that NWBO would announce its earliest “active discussions” with other parties is unlikely. In other words, August 2023 is unlikely a starting date of any kind.
3. At the December 2022 ASM, LP stated that they looked forward to proceeding with these combination trials once the MAA was cemented.
4. At least some of the combo trials forecast
By LP we’re conceptually designed with the parties a few years ago.
So while it’s great to cut and paste a rundown of the Prometheus timeline, one might suspect NWBO is simply waiting for some cement to cure.
There is a tendency, sometimes, to slip into the notion that delay in moving forward is bottlenecked by the CI Pharma companies’ stranglehold on the biotech economy. Particularly the PD-1 group. Perhaps that was/is partly true, but obviously coming to an end.
On the other hand, there was Covid, resulting in well known supply chain shortages for companies around the world, and the UK morphing out of its Brexit cocoon. These obviously slowed progress.
Right now, it seems like Advent’s, MHRA’s and the UK’s chance to shine, and, along with alternative interim reimbursement
pathways in the UK, step up for their citizens, whom are not fairing well in GBM treatment under the old system.
Advent is incentivized to use its brief but forthcoming pre-Eden commercial era well, in order to help fellow citizens, help prepare for eventual Eden commercial engineering runs, and ultimately transition much of their production workforce from manual UK production, into automated UK production for UK, Europe and beyond.
It’s hard to imagine more humanitarian and economic motivation for Advent, Flaskworks/NWBO and the UK to get on it and start easing the suffering of fellow citizens, and eventually, patients around the globe similarly situated.
Would any possible buyout suitor want to nip in the bud LP’s plans for combination trials with several parties because would be acquirer would not want to be tethered by such contracts?
If so, wouldn’t this justify paying a supreme premium above the PPS in order to avoid such tethers?
Any idea why Lovance would finance (211 million) before Market had a chance to weigh in on Friday evening’s approval? What are they expecting after the opening bell, and why?
The nature preprint article is poly-iclc with autologous dc.
Different from:
The others you speak of also include CI.
I see your logic now. Thank you.
Recent movement.
1. Combination patent application in Europe to be granted, includes both DCVax-l (lysate pulsed) and/or DCVax-Direct (partial maturation) with checkpoint inhibitors.
2. Over 60 days since MAA was filed.
3. MHRA and FDA looking at further cooperation.
4. Nature Journal article on DC/poly-iclc combination study nearing publication. Primary completion date for study occurred twenty days ago.
5. Active negotiations with other parties for combination trials going on for over a year, awaiting MAA to be “cemented.”
6. Large pharma struggling to adapt to upcoming patent cliffs.
7. Cohen/Milstein/Posner about to file second amended complaint, and with it, formulaic method to arrive at loss causation.
8. Ihub message board drifting toward speculation on possible suitors and valuations regardless of PPS suppression.
Can you expound on that? Regardless, thanks for your response.
So, let’s pretend a buyout occurs. What is the new pharma likely to do with:
1. NWBO’s Legal case against market makers?
2. The derivative case against NWBO?
I think plaintiffs can also file for summary judgment.
Ask a legal eagle if it will be a judge or jury trial, if, on the rare chance it does not resolve before trial.
“What one woman can do….”
It’s Biosect’s link, not mine. Numbnuts.
Ex and I have gone back and forth on this before.
The U.S. patent application that Ex brought up has a continuance filed, not published, utilized that graph shared by Dr. Liau with Dr. Musella. It has since, uncharacteristically disappeared, the document is no longer accessible.
I’ll look.
Edit : ….patent application that you brought up has a continuance filed….
Dr. Liau is one of the inventors and is on NWBO’s SAB. UCLA is an assignee. NWBO is an assignee. You and someone nicer are from whistle higher? Am I right?
We’ve had this discussion. The U.S. patent that you brought up has a continuance filed, not published, utilized that graph shared by Dr. Liau with Dr. Musella. It has since, uncharacteristically disappeared, the document is no longer accessible.
Here’s some more discussion on that from way back when. I’m certain NWBO must have already known this. Their combo patent application was in 2013/2014.
In short:
#dcvax $nwbo #gbm
— Peter Davis (@peter_brit) February 19, 2024
This simply cannot be overstated as to how important this is.
With known safety concerns relating to CI's already known:
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United Stateshttps://t.co/bKk3KuVXbn.…
You “wait” for acceptance, I believe MHRA has already confirmed it.
The judge has only now ordered to adopt the magistrate’s recommendations. You are confused. It is now within the 30 day window for plaintiff to file the second amended complaint. The plaintiff’s attorneys have stated in filings that they are prepared to provide the information the magistrate recommended/requested.
The MAA is currently “held” by MHRA.
In cases like most of the stocks you probably invest in, if an maa is not held after 30 days, that means it was not accepted (validated) and a new maa would have to be filed.
Beyond 30 days from submission, MHRA confirmed the DCVax-l maa was being “held” by MHRA.
Inquirig, you are responding to yourself again. Slow down and try to remember when you are changing handles.